News

Novartis wins first US approval for Cosentyx in polymyalgia rheumatica

What's the news? The US Food and Drug Administration (FDA) approved Novartis' Cosentyx (secukinumab) 150 mg on 17 November 2026 for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate tapering off them. It is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for PMR, and the 11th US indication for Cosentyx.

Why it matters: PMR is a common inflammatory disease, mainly affecting people over 50 (about 966,000 people in the US), that causes acute pain and stiffness in the shoulders, neck and hips. The standard of care has long been steroids, but relapses are frequent — affecting up to 40% of patients within the first year — and long-term steroid use raises the risk of osteoporosis, cardiovascular disease and diabetes. Cosentyx offers an alternative to long-term steroid use for patients who do not respond adequately to them.

How it works: Cosentyx is a fully human biologic that blocks interleukin-17A, a signalling protein involved in the inflammation underlying several immune-mediated diseases. Approval was based on the pivotal Phase 3 REPLENISH trial (a global, randomised, double-blind, placebo-controlled study across 27 countries), in which patients also followed a 24-week steroid-tapering regimen. Adults treated with Cosentyx 150 mg achieved sustained remission at twice the rate of placebo at week 52 (40.5% vs 20.5%), and the safety profile was consistent with Cosentyx's established record across a decade of use. The PMR indication was already approved in the EU; reviews continue in Japan and other countries.

Read more: Novartis, 17 November 2026

More top stories